Saturday, September 19, 2026

Interest Rates & Indices

2 articles

Rate Traders Slash 2026 Cut Expectations to 0.2% as ECB Warns on Energy Prices

Rate Traders Slash 2026 Cut Expectations to 0.2% as ECB Warns on Energy Prices

Interest rate markets have sharply reversed course, with only 0.2% of traders now expecting Fed rates to fall to 3.25-3.5% by end-2026, down from December projections of two cuts. The shift comes as ECB officials warn they cannot rule out April rate changes if oil prices remain elevated, with crude up 3% on Middle East tensions.

LM Salvado
Fed Officials Signal No More Rate Cuts as Tariff Inflation Persists, Bond Yields Hold Above 4.2%

Fed Officials Signal No More Rate Cuts as Tariff Inflation Persists, Bond Yields Hold Above 4.2%

Multiple Federal Reserve regional presidents are signaling reluctance to cut rates further, citing tariff-driven inflation and strong economic growth. The shift toward a prolonged higher-for-longer stance is pressuring equity valuations while keeping 10-year Treasury yields elevated. Traders are repricing rate cut expectations for 2026.

ViaNews Editorial Team (Markets)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com